NICE Recommends Albireo’s Bylvay®(odevixibat) for All PFIC Types
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that the National Institute for Health and Care Excellence (NICE) has issued guidance that recommends Bylvay (odevixibat) for the treatment of all types of progressive familial intrahepatic cholestasis (PFIC) in people aged six months and older.
Bylvay is a potent, non-systemic ileal bile acid transport inhibitor (IBATi), administered as a once-daily treatment. With this final recommendation under the Highly Specialised Technologies (HST) pathway, Bylvay will be funded for use within 90 days in the National Health Service in England, Wales and Northern Ireland.
“It’s incredibly gratifying to see children with PFIC gain access to the first ever non-surgical treatment option for a disease that causes tremendous suffering, in many cases leading to cirrhosis and liver failure within the first 10 years of life,” said Richard Thompson, Professor of Molecular Hepatology at King’s College London and principal investigator of PEDFIC 1 & PEDFIC 2 studies. “Odevixibat represents an important advance for patients, allowing us to respond to urgent treatment needs with a drug option that can provide clinically meaningful benefits and the ability to reduce the disease burden for patients and families who otherwise face PEBD surgery or liver transplant.”
“Children living with PFIC have an incurable devastating disease that causes pruritus which was treated with liver transplantation. Until the recommendation from NICE, we’ve had no approved drug options to address this devastating disease,” said Professor Deirdre Kelly, Consultant Paediatric Hepatologist, Liver Unit, Birmingham Women’s and Children’s Hospital and University of Birmingham. “My colleagues and I are delighted that we now have an effective non-surgical treatment option to reduce the burden of this disease on children and families and improve the quality of their lives.”
The final NICE recommendation is aligned to the European Marketing Authorization (EMA) and UK Medicines and Healthcare Products Regulatory Agency (MHRA) approval as the first medicine for the treatment of PFIC, a rare and devastating disorder affecting young children that causes progressive, life-threatening liver disease. Patients with PFIC have impaired bile flow, or cholestasis, the resulting bile build-up in liver cells causes liver disease and symptoms such as intense itching, poor sleep, delayed growth and diminished quality of life. The harmful impacts of the disease extend beyond the individuals with PFIC to those caring for them as shown by the 2022 multinational PICTURE study, which revealed PFIC negatively affects caregivers’ quality of life, relationships and career prospects.
"Bylvay is a ground-breaking drug that has the potential to transform the lives of children and young people living with PFIC and the families that care for them who experience terrible suffering and quality of life," said Alison Taylor, patient advocate and outgoing Chief Executive of Children’s Liver Disease Foundation (CLDF). “We are delighted that Bylvay will be available to patients in the UK and commend NICE for their review and recommendation.”
The NICE recommendation is based on data from PEDFIC 1 and PEDFIC 2, the largest, global, Phase 3 trials ever conducted in PFIC.
In PEDFIC 1, a randomised, double-blind, placebo-controlled study, Bylvay met both its pruritus (p=0.004) and serum bile acid (p=0.003) primary endpoints and was well tolerated with low incidence of drug-related diarrhea/frequent bowel movements (9.5% of treated patients vs. 5.0% of placebo patients).
PEDFIC 2, a long-term, open-label Phase 3 extension study, affirmed Bylvay delivered sustained reductions in serum bile acid as well as improvements in pruritus assessments, growth and sleep and markers of liver function in patients treated up to 48 weeks in an interim analysis. Across both studies, Bylvay was well tolerated. The most common adverse reactions for Bylvay were diarrhea, liver test abnormalities, vomiting, abdominal pain, and fat-soluble vitamin deficiency. There were no serious treatment-related adverse events reported in any clinical study with Bylvay.
“The positive NICE recommendation was rapidly obtained, within six months of MHRA approval, and it reinforces the significant benefit Bylvay offers to patients. We are pleased that more children will now have access to Bylvay,” said Ron Cooper, President and Chief Executive Officer of Albireo. “Additional pricing and reimbursement discussions for Bylvay are ongoing across Europe and are being accelerated wherever possible. The early response has been encouraging, for example, in France Bylvay has received an SMR ‘Important’ and ASMR III from the HAS Transparency Committee.”